327 related articles for article (PubMed ID: 18813113)
1. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
4. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory chronic GVHD with rituximab: a GITMO study.
Zaja F; Bacigalupo A; Patriarca F; Stanzani M; Van Lint MT; Filì C; Scimè R; Milone G; Falda M; Vener C; Laszlo D; Alessandrino PE; Narni F; Sica S; Olivieri A; Sperotto A; Bosi A; Bonifazi F; Fanin R;
Bone Marrow Transplant; 2007 Aug; 40(3):273-7. PubMed ID: 17549053
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
7. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease.
Szabolcs P; Reese M; Yancey KB; Hall RP; Kurtzberg J
Bone Marrow Transplant; 2002 Sep; 30(5):327-9. PubMed ID: 12209356
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
10. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
11. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
12. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
Barrera MV; Mendiola MV; Bosch RJ; Herrera E
J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643
[TBL] [Abstract][Full Text] [Related]
13. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
15. [Delayed response to rituximab of cold agglutinin haemolytic disease].
Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
D'Arena G; Califano C; Annunziata M; Tartarone A; Capalbo S; Villani O; Amendola G; Pietrantuono G; Ferrara F; Pinto A; Musto P; D'Arco AM; Cascavilla N
Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766
[TBL] [Abstract][Full Text] [Related]
17. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
Faurschou A; Gniadecki R
Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
19. Chronic graft-versus-host disease.
Cutler C; Antin JH
Curr Opin Oncol; 2006 Mar; 18(2):126-31. PubMed ID: 16462180
[TBL] [Abstract][Full Text] [Related]
20. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects.
Terrier B; Delmas Y; Hummel A; Presne C; Glowacki F; Knebelmann B; Combe C; Lesavre P; Maillard N; Noël LH; Patey-Mariaud de Serre N; Nusbaum S; Radford I; Buzyn A; Fakhouri F
Nephrol Dial Transplant; 2007 May; 22(5):1369-76. PubMed ID: 17255123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
